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Abstract
Background: Reported series of a distal pancreatectomy with celiac axis resection (DP-CAR) are
either small or not adequately controlled. The aim of this analysis was to report a multicentre series of
modified Appleby procedures with a comparison group to determine the relative operative risk.
Methods: Data were gathered through the American College of Surgeons-National Surgical Quality
Improvement Program (ACS-NSQIP) Pancreatectomy Demonstration Project. Over 14 months, 822
patients underwent a distal pancreatectomy at 43 institutions. Twenty of these patients (2.4%) also
underwent a celiac axis resection. DP-CAR patients were matched by age, gender, BMI, serum albu-
min, ASA class, gland texture, duct size and pathology to 172 patients undergoing DP alone.
Results: The majority of DP and DP-CAR patients had adenocarcinomas (61% and 60%). The median
operative time for a DP alone was shorter than for a DP-CAR (207 versus 276 min, P < 0.01). Post-
operative acute kidney injury (1% versus 10%, P < 0.03) and 30-day mortality were higher after a
DP-CAR (1% versus 10%, P < 0.03).
Conclusion: A distal pancreatectomy with celiac axis resection is associated with increased operative
time, post-operative acute kidney injury and a 10% operative mortality. The decision to offer a modi-
fied Appleby procedure for a body of pancreas tumour should be made with full disclosure of the
increased risks.
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Introduction
Pancreatic cancer remains the fifth leading cause of cancer
death in the United States. A pancreatectomy provides the only
chance of long-term survival for patients with pancreatic can-
cer and has become safer over the past three decades owing to
advancements in radiographical imaging, surgical technique
and critical care.1 As experience performing a pancreatectomy
has grown, some surgeons have taken a more aggressive opera-
tive approach towards locally advanced pancreatic tumours of
the body and tail of the pancreas with involvement of the
celiac axis.2
In 1953, Lyon Appleby proposed en bloc resection of the
celiac trunk with a total gastrectomy and a distal pancreatec-
tomy for the treatment of locally advanced gastric cancer.3 A
modification of the Appleby procedure has been described for
locally advanced adenocarcinoma of the body and tail of the
pancreas that invades the celiac axis. This operation consists
of a distal pancreatectomy with en bloc celiac axis resection
(DP-CAR) with preservation of the stomach.4,5 Previous
reports indicate that outcomes after a DP-CAR are comparable
to a distal pancreatectomy (DP) alone but mostly summarize
small, single-institution, retrospective experiences without a
control cohort.5–8
Using data gathered through the American College of
Surgeons-National Surgical Quality Improvement Program
(ACS-NSQIP) Pancreatectomy Demonstration Project (PDP), we
report a multi-institutional series of modified Appleby procedures
This study was presented at the Annual Meeting of the AHPBA, 11-15
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with a comparison group of distal pancreatectomies to determine
the relative risks of each operation.
Patients and methods
Pancreatectomy Demonstration Project
The ACS-NSQIP is a standardized programme that prospec-
tively collects patient characteristics, processes of care and
adverse outcomes within 30 days of operation in order to eval-
uate risk-adjusted hospital performance with regards to surgi-
cal care.9 Together with ACS-NSQIP, the PDP is a collection
of 256 Health Insurance Portability and Accountability Act
(HIPAA) compliant variables gathered prospectively on 2805
patients undergoing a pancreatic resection from 43 institutions
(median = 63 per institution, range 3–213) from November
2011 through to December 2012 and has been previously
described.10–14 This study was exempt from review by the
Institutional Review Board at Indiana University School of
Medicine.
Patient population
The ACS-NSQIP PDP database was queried to identify patients
having undergone an elective DP-CAR, also known as a modi-
fied Appleby procedure. Patients treated with DP-CAR were
matched to patients undergoing a DP without a celiac trunk
resection according to age, gender, body mass index (BMI),
serum albumin, American Society of Anesthesiologists (ASA)
class, pancreatic gland texture, pancreatic duct size, and patho-
logical diagnosis. These parameters were chosen because other
analyses of the PDP and ACS-NSQIP databases have demon-
strated that they are independent variables that predict adverse
outcomes. Data were not available on which patients also had
a splenectomy.
Surgical outcomes
Post-operative complications documented as part of ACS-NSQIP
and the respective definitions have been published previously.15
In addition to the standard ACS-NSQIP variables, 24 addi-
tional pancreas-specific variables were collected as part of the
PDP and include the presence of pre-operative jaundice or a
biliary stent, chemotherapy and/or radiation in the 90 days
prior to surgery, operative approach, pancreatic duct size,
pancreatic gland texture, vascular resection, pancreatic recon-
struction, intestinal reconstruction, intra-operative drain place-
ment, drain amylase on post-operative day one, the last day of
drain removal, a post-operative pancreatic fistula, delayed gas-
tric emptying, organ-space infection requiring percutaneous
drainage and pancreatic pathology.10 Criteria for diagnosis of a
pancreatic fistula included persistent drainage (a drain output
of any measurable volume of fluid on or after post-operative
day 3) of amylase-rich fluid (an amylase content >3 times the
serum amylase activity) AND one of the three following crite-
ria: drain continued longer than 7 days, percutaneous drainage
performed, or reoperation performed. Alternatively, if a clinical
diagnosis of a pancreatic fistula determined by the attending
surgeon was made and one of the previous three criteria were
met, then the patient was diagnosed with a pancreatic fistula.
Complications were classified by the Clavien–Divido methodol-
ogy.16 Of the variables collected by the PDP, pathological
information was recorded, but the completeness of a resection,
as measured by R classification, was not collected. Standardiza-
tion of the R classification for pancreatic cancer remains an
important area of current controversy. For the purpose of the
present study, margin status was neither standardized across
institutions nor was this information collected.
Statistical analysis
Continuous variables were expressed as median with range or
mean  standard error of mean (SEM) and compared using
the Student’s t-test for 2 9 2 comparison. Categorical variables
were compared using two-tailed Fisher’s exact and Wilcoxon’s
rank sum when appropriate. Statistical significance was set at
P ≤0.05.
Results
Patient demographics
Over 14 months, data were collected on 822 patients who
underwent a distal pancreatectomy at 43 institutions. Twenty
of these patients (2.4%) underwent a DP-CAR. DP-CAR was
reported from 16 institutions (37%), with a range of 1–3
patients per institution. While we have not collected the num-
ber of pancreatectomies performed annually at each institution
by national standards, 37 out of 43 (86%) were considered
high-volume centres. Patients within the DP-CAR group were
matched for age, gender, BMI, pre-operative serum albumin,
ASA class, pancreatic gland texture and duct size as well as
pathology to 172 patients undergoing DP without CAR. Com-
parison of patient demographics of the two cohorts is shown
in Table 1. Within the group of patients with adenocarcinoma,
25% of those who underwent a DP-CAR received neoadjuvant
therapy (chemotherapy  radiotherapy) compared with 8% of
patients who underwent DP alone (P = 0.10).
Operative factors
Operative details of the two cohorts are shown in Table 2. The
operative approach (open versus minimally invasive) was simi-
lar in both groups. Two DP-CAR operations were completed
laparoscopically (10%). Five patients (25%) who underwent a
DP-CAR were started laparoscopically, most likely for staging,
but three of these were converted to an open operation.
Patient cohorts were similar with respect to both pancreatic
gland texture and intra-operative drain placement. A trend was
noted towards a decreased number of patients requiring blood
transfusions after a DP alone compared with DP-CAR (18%
versus 35% P = 0.08) (Fig. 1). The median operative time for
DP alone was over 60 min less than for a DP-CAR (207 versus
276 min, P < 0.01) (Table 2, Fig. 1).
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Post-operative outcomes
Individual patient outcomes after a DP-CAR are listed in
Table 3. The most common complications after a DP-CAR
were acute kidney injury (10%) and a pancreatic fistula (10%).
Acute kidney injury was defined as a clinical condition associ-
ated with rapid, steadily increasing azotemia (increase in
BUN) and rising creatinine to a level above 3 mg/dl.14 Both
patients with acute kidney injury also required blood transfu-
sion and reoperation and died after their post-operative com-
plications. Neither patient had been treated with neoadjuvant
therapy. The overall 30-day mortality after a DP-CAR was
10% (n = 2).
Post-operative outcomes of DP alone compared with a
DP-CAR are shown in Table 4. The overall morbidity for DP
and DP-CAR patients was comparable (36% versus 35%,
P = 1.0) (Fig. 2). However, 30-day mortality was significantly
higher in those after a DP-CAR (1% versus 10%, P < 0.03)
(Fig. 3). No deaths occurred in either cohort between 30 and
90 days. Compared with patients who underwent a DP alone,
patients after a DP-CAR tended to require reoperation more
frequently (2% versus 10%) and have a longer hospital stay
(median 6 versus 8 days), but these differences did not reach
statistical significance. No significant differences were observed
in pancreatic fistulae (15% versus 10%) (Fig. 2), need for per-
cutaneous drain placement (9% versus 5%), or delayed gastric
emptying (5% versus 0%). In addition, no significant differ-
ences were noted between cohorts with respect to the develop-
ment of infectious, pulmonary, or cardiovascular complications.
However, a statistically significant increase in the proportion of
patients who developed acute kidney injury was observed in
patients after a DP-CAR (1% versus 10%, P < 0.03).
Complications were also stratified according to the Clavien–
Dindo classification.16 The highest-grade complication for each
patient was determined and is presented in Table 5. No differ-
ences were found in the distribution of complication grades
between DP and DP-CAR patients.
Discussion
Surgery remains the only chance for long-term survival and a
cure for patients with pancreatic cancer. However, owing to
the anatomic location of the pancreas only 10% of tumours of
the body and tail of the pancreas, are resectable at the time of
presentation.17 To increase the number of resectable patients,
surgeons have become more aggressive at operating on locally
advanced pancreatic tumours. The modified Appleby proce-
dure has been described for malignancies of the body and
tail of the pancreas and consists of a DP and a DP-CAR with
Table 1 Patient population
DP DP-CAR P-value
Total patients, n 172 20
Age, year median (range) 66 (29–89) 64.0 (35–83) 0.71
Gender, n (%)
Male 57 (33) 6 (30) 1.00
Female 115 (67) 14 (70)
Race
White 151 (88) 18 (90) 1.00
Black 12 (7) 1 (5)
Other 9 (5) 1 (5)
Body mass index, kg/m2
Median (range)
26.6 (16.1–42.6) 25.3 (20.0–38.0) 0.93
Albumin, g/dl
median (range)
4.1 (3.1–5.3) 4.2 (3.3–4.8) 0.65
Creatinine, g/dl
median (range)
0.80 (0.48–2.18) 0.80 (0.60–1.66) 0.49
ASA score,
mean (SEM)
2.70  0.04 2.60  0.11 0.47
1 1 (1) 0 (0)
2 54 (31) 8 (40)
3 112 (65) 12 (60)
4 5 (3) 0 (0)
Pathology, n (%)
Adenocarcinoma 109 (61) 12 (60) 1.00
Endocrine neoplasm 22 (12) 3 (15)
IPMN 8 (4) 1 (5)
Cystic neoplasm 11 (6) 1 (5)
Othera 22 (12) 3 (15)
Neoadjuvant
therapyb n (%)
9/109 (8) 3/12 (25) 0.10
a
The exact tumour type is not available.
b
In patients with adenocarcinoma.
ASA, American Society of Anesthesiologists; IPMN, intraductal papil-
lary mucinous cystic neoplasm.
Table 2 Operative factors
DP DP + CAR P-value
Total patients, n 172 20
Operative approach, n (%)
Open 129 (75) 18 (90) 0.17
Laparoscopic 36 (21) 2 (10)
Robotic 7 (4) 0 (0)
Gland texture, n (%)
Soft 45 (26) 7 (35) 0.16
Intermediate 5 (3) 1 (5)
Hard 20 (12) 4 (20)
Unknown 102 (59) 8 (40)
Intra-operative
drain placement
148 (86) 14 (70) 0.10
Blood transfusions 31 (18) 7 (35) 0.08
Operative time (min)
median (range)
207 (66–581) 276 (164–617) <0.01
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preservation of the stomach for tumours that invade the celiac
axis.4,5 Using data gathered through the ACS-NSQIP PDP, we
compared a multi-institutional series of Appleby procedures
with a DP alone to determine the relative risk. Our analysis
revealed a significant increase in operative time, the incidence
of acute kidney injury, and operative mortality in patients
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Figure 1 Operative time and blood transfusions
Table 3 Patient outcomes after distal pancreatectomy with celiac artery resection
Patient no. Age and
gender
Operative
time (min)
Pathology Post-operative complication Clavien–Dindo
classification
Length of stay
1 40 F 270 Othera – 0 8
2 75 F 212 PDAC – 0 6
3 66 F 284 PDAC Panc fistula, OSI, sepsis III 11
4 78 M 298 Othera – 0 9
5 60 M 440 PDAC Bleed/transfusion II 9
6 61 F 370 PDAC Bleed/transfusion II 6
7 71 F 181 NET – 0 6
8 60 F 291 Othera SSI I 8
9 57 F 164 NET – 0 10
10 83 F 260 PDAC Bleed/transfusion II 8
11 61 F 255 PDAC – 0 5
12 83 M 477 PDAC Bleed/transfusion, ARF,
unplanned intubation,
ventilator > 48h
IV Expired day 6
13 75 F 225 NET – 0 8
14 66 M 249 PDAC – 0 4
15 69 F 331 PDAC Bleed/transfusion, ARF,
pneumonia, septic
shock, DVT,
IV Expired day 14
16 53 M 617 PDAC – 0 6
17 71 F 239 IPMN – 0 5
18 62 M 450 PDAC Bleed/transfusion, panc fistula UTI II 9
19 59 F 282 PDAC Bleed/transfusion II 10
20 35 F 199 Cyst – 0 7
PDAC, Pancreatic ductal adenocarcinoma; NET, pancreatic neuroendocrine tumor; IPMN, intraductal papillary mucinous cystic neoplasm; Cyst,
pancreatic cystic neoplasm.
a
The exact tumour type is not available.
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following distal pancreatectomy with celiac axis resection com-
pared to distal pancreatectomy alone.
Previous reports comparing a DP alone with a DP-CAR are
conflicting and are limited because they are small, single-insti-
tutional, retrospective reviews without a control cohort.5–8,18
In our study comparing the outcomes of 20 patients after a
DP-CAR with a matched cohort of 172 patients with DP alone,
we found that the overall morbidity was comparable, but a sig-
nificant increase in 30-day mortality was observed in those
who underwent a DP-CAR (1% versus 10%, P < 0.01). The
mortality from our study is comparable to those published
previously. In one of the largest US series, Baumgartner et al.19
reported a 90-day mortality of 18% after a DP-CAR in patients
who had received neoadjuvant chemoradiation therapy. Wu
et al. reported a mortality of 9% in their series from China,
and in the largest Japanese series (n = 42), Tanaka and col-
leagues reported a mortality of 4.8%.18–20 Based on historical
controls where the mortality from segmental pancreatectomy is
<1%, an increase in mortality after a DP-CAR has only been
inferred.1,21 Our study is the first to report increased 30-day
mortality associated with DP-CAR compared with a matched
cohort having been treated with DP alone. Eight different pre-
dictive variables were used to identify the matched cohort of
DP patients. However, a type I statistical error owing to the
small sample size is possible.
The overall incidence of post-operative complications in
patients after a DP-CAR (35%) in the present study was nearly
identical to those having undergone a DP alone (36%) and is
comparable to that of previously published report.11,14,18–23
However, the incidence of post-operative acute kidney injury
in the present study was significantly higher in patients after a
DP-CAR (1% versus 10%, P = 0.03). In addition, a greater
percentage of patients treated with DP-CAR required blood
transfusions and/or a return to the operating room, but these
differences did not reach statistical significance. Both mortali-
ties that occurred after a DP-CAR were in patients who
received peri-operative blood transfusions, developed acute
kidney injury and required reoperation.
Compared with most of the literature on a DP, the inci-
dence of a pancreatic fistula in the DP (15%) and DP-CAR
(10%) groups in this study was relatively low. This observation
is most likely the result of two factors: (i) the high incidences
of pancreatic cancers and (ii) the use of neoadjuvant therapy.
The fact that patients with pancreatic cancer have more fibrosis
and fewer pancreatic fistulae is well documented.24 In addition,
a recent report from the PDP demonstrated that patients who
received neoadjuvant radiation were less likely to develop a
pancreatic fistula.12 In the present analysis, one-fourth of the
DP + CAR patients received neoadjuvant therapy whereas 8%
of the matched DP patients also received chemotherapy and/or
radiation prior to the operation. The method of closing the
pancreatic remnant was not collected in the present study and,
thus, whether the two cohorts were similar with respect to this
variable is not known. However, a recent analysis suggests that
one method of closure is not superior to another.25
A limitation to the present study is the inability to report on
oncological outcomes after a DP-CAR. The reported median
survival after a DP-CAR ranges from 9.3 to 20.8 months.2,26
Yamamoto et al.27 found an increase in the median survival
after a DP-CAR compared with unresectable patients with
locally advanced disease burden (9.3 versus 20.8 months,
P = 0.01) and no difference in survival when compared with
patients after a DP alone. Yet, with a reported morbidity in
that series of 92%, and the known risks of severe gastropathy
or hepatic ischemia, some surgeons have been slow to adopt
such an aggressive surgical approach in the absence of more
Table 4 Post-operative morbidity
DP DP-CAR P-value
Total patients, n 172 20
General
Overall morbidity 64 (36) 7 (35) 1.00
30 day mortality 1 (1) 2 (10) 0.03
Death after 30 daysa 0 (0) 0 (0) 1.00
Overall mortality 1 (1) 2 (10) 0.03
Reoperation 3 (2) 2 (10) 0.09
Length of stay, daysb 6 (2–43) 8 (4–14) 0.65
Gastrointestinal
Pancreatic fistula 24 (15) 2 (10) 1.00
Percutaneous drain 15 (9) 1 (5) 1.00
Delayed gastric emptying 8 (5) 0 (0) 1.00
Infectious
Any SSI 11 (6) 1 (5) 1.00
Organ space SSI 10 (6) 1 (5) 1.00
UTI 8 (5) 1 (5) 1.00
Pneumonia 6 (4) 1 (5) 1.00
Sepsis 5 (3) 1 (5) 1.00
Septic shock 4 (2) 1 (5) 1.00
Pulmonary
Unplanned intubation 3 (2) 1 (5) 1.00
Pulmonary embolism 2 (1) 0 (0) 1.00
Ventilator > 48 h 4 (2) 1 (5) 1.00
Cardiovascular
DVT 7 (4) 1 (5) 1.00
Stroke 0 (0) 0 (0) 1.00
MI 0 (0) 0 (0) 1.00
Renal
Acute kidney injury 1 (1) 2 (10) 0.03
SSI, surgical site infection; UTI, urinary tract infection; DVT, deep vein
thrombosis; MI, myocardial infection.
a
Death between 30 and 90 days.
b
Median (range).
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robust survival data.26 Only one series to date has shown a
reduced median survival in patients treated with a DP-CAR
compared with a DP alone (9.7 versus 30.9 months, P =
0.033). However, the rate of R1 resection was 44% in DP-CAR
versus 22% in those who received DP.28 In the absence of ade-
quate follow-up and a control cohort of unresectable patients,
it is unknown whether the short-term increase in mortality
after a DP-CAR in our series could be offset by a longer
3- and 5-year survival for patients after a DP-CAR compared
with patients without a surgical option.
With failure owing to metastatic disease driving survival in
most patients, the utility of such an aggressive approach to
locally advanced pancreatic cancer is largely dependent on the
biology of the tumour. In most series, local control with R0
resection rates and local recurrences after a DP-CAR are com-
parable to a DP alone, with the majority of patients succumb-
ing to their disease as a result of distant metastases. The
ability to predict patterns of failure based on tumour biology
remains a major challenge in defining patients who would
benefit from such an aggressive surgical approach. Previous
reports have demonstrated that the loss of SMAD4 and the
increased expression of nuclear hypoxia-inducible factor 1a
(HIF-1a) are important predictors for distant failure in
patients undergoing resection of pancreatic adenocarci-
noma.29,30 More recently, new candidate drivers of pancreatic
carcinogenesis (KDM6A and PREX2) have been discovered,
and patterns of variation in chromosomal structure based on
whole-genome sequencing have facilitated the classification of
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PDACs into four subtypes: stable, locally rearranged, scattered
and unstable.31 While the implications of these findings are
broad, their clinical utility in selecting patients that would
benefit from a more aggressive surgical approach remains to
be seen.
Another limitation of the present study is the inability to
report on the quality-of-life measures, pain scales, or the
amount and duration of narcotic use. Patients who undergo a
DP-CAR experience a reduction in abdominal pain and an
improved quality of life related to resection of the celiac plexus
at the time of surgery.6,18 The pain caused by neural invasion
of the celiac plexus is debilitating and characteristically refrac-
tory to systemic analgesia. Wu et al.18 found that 86% of
patients after a DP-CAR had relief of back pain compared with
only 8% of patients who were managed medically without a
surgical resection. Adequate post-operative analgesia is inti-
mately tied to patient satisfaction and is an important quality
measure that has yet to be included as a variable abstracted by
NSQIP.
In summary, the purpose of this analysis was to determine
whether a DP-CAR has added risks compared with a DP alone.
Overall, DP-CAR is associated with a significanly increased
operative time, acute kidney injury and a 10% operative mor-
tality in our cohort. The decision to offer a modified Appleby
procedure should be made with full disclosure of the increased
risks. In the situations where a modified Appleby procedure is
the only possible surgical option neoadjuvaunt therapy should
be undertaken, and the informed consent process should
include disclosure of increased complications and mortality.
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